Orasis Pharmaceuticals is a privately held ophthalmic company focused on developing and commercializing therapies for presbyopia, the age-related loss of near vision. This weekly recap highlights the company’s latest efforts to deepen prescriber engagement and expand education around presbyopia eye-drop treatments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
During the week, Orasis spotlighted its participation in the VS The Exchange meeting hosted by Vision Source, a major optometry network celebrating its 35th anniversary. The company’s LinkedIn updates emphasized clinical education on presbyopia eye drops and featured optometrists Jade Coats and Bobby “Chip” Wood Jr. addressing misconceptions about these therapies.
The educational sessions focused on clarifying how presbyopia drops fit into a flexible treatment toolbox for improving near vision. By highlighting clinician-led myth-busting, Orasis signaled a strategy aimed at fostering greater clinical acceptance and comfort with this emerging treatment category among eye-care professionals.
These efforts build on Orasis’s broader Presbyopia Awareness Month campaign, where the company previously highlighted prescriber Dámaris Raymondi, O.D., FAAO. That initiative promoted presbyopia eye drops as an “exciting new category” and directed audiences to safety information and educational resources, underscoring a balanced message around benefits and risks.
From a business perspective, Orasis’s continued focus on practitioner education and alignment with organized optometry suggests an execution-driven commercialization strategy. Stronger ties with influential networks like Vision Source could help support future product uptake, reinforce brand positioning in the presbyopia segment, and underpin long-term prescription growth if its therapies gain broad adoption.
Overall, the week underscored Orasis Pharmaceuticals’ commitment to awareness, education, and relationship-building with eye-care providers. By prioritizing clinical credibility and category development, the company is working to solidify its role in the competitive market for pharmacologic solutions to presbyopia and to support its future growth prospects in vision-care therapeutics.